Canada's MindWalk Q3 revenue rises on US growth

Overview

• Canada Bio-Native AI firm's fiscal Q3 revenue grew 52% yr/yr to C$4.2 mln

• Company signed first annual enterprise LensAI platform contract, shifting to recurring revenue

• US revenue doubled as company focused strategically on North America

Outlook

• MindWalk says LensAI platform rollout is scaling across its client base

• Company expects continued focus on North America due to favorable regulatory environment

• MindWalk advancing dengue, GLP-1, and influenza programs with upcoming milestones

Result Drivers

• NORTH AMERICA FOCUS - Co said US revenue doubled year over year, driven by strategic focus on North America and new biologics operations in Boston and Cambridge

• RECURRING REVENUE CONTRACT - Co signed first annual enterprise LensAI platform contract, shifting part of revenue from project-based to contracted and recurring

Company press release: ID:nBw1LlMBza

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for MindWalk Holdings Corp is $4.00, about 212.5% above its March 11 closing price of $1.28

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.